Table of Contents

company-logo

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

IDEAYA Biosciences Dividend Announcement

• IDEAYA Biosciences does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on IDEAYA Biosciences dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

IDEAYA Biosciences Dividend History

IDEAYA Biosciences Dividend Yield

IDEAYA Biosciences current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing IDEAYA Biosciences stock? Use our calculator to estimate your expected dividend yield:

IDEAYA Biosciences Financial Ratios

P/E ratio-13.42
PEG ratio0.13
P/B ratio2.02
ROE-19.42%
Payout ratio0.00%
Current ratio22.93
Quick ratio22.93
Cash Ratio9.84

IDEAYA Biosciences Dividend FAQ

Does IDEAYA Biosciences stock pay dividends?
IDEAYA Biosciences does not currently pay dividends to its shareholders.
Has IDEAYA Biosciences ever paid a dividend?
No, IDEAYA Biosciences has no a history of paying dividends to its shareholders. IDEAYA Biosciences is not known for its dividend payments.
Why doesn't IDEAYA Biosciences pay dividends?
There are several potential reasons why IDEAYA Biosciences would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will IDEAYA Biosciences ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While IDEAYA Biosciences has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is IDEAYA Biosciences a dividend aristocrat?
IDEAYA Biosciences is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is IDEAYA Biosciences a dividend king?
IDEAYA Biosciences is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is IDEAYA Biosciences a dividend stock?
No, IDEAYA Biosciences is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy IDEAYA Biosciences stocks?
To buy IDEAYA Biosciences you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy IDEAYA Biosciences stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.